Outcome of Board Meeting- Financial Results

i$Biocon Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2026-27/48 August 05, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol - BIOCON Dear Sir/Madam, Subject: Outcome of the Board Meeting Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations, 2015’), we wish to inform you that the Board of Directors at its meeting held today, i.e. on Wednesday, August 05, 2026, inter alia, has approved the unaudited financial results (standalone and consolidated) of the Company prepared as per the Indian Accounting Standards (Ind-AS) for the quarter ended June 30, 2026. A copy of the aforesaid unaudited financial results along with the limited review report from the statutory auditors is enclosed herewith. The above information will also be available on the website of the Company at www.biocon.com. Further, the Board Meeting commenced at 2:30 p.m. and concluded at 3:34 p.m. Kindly take the above information on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance officer ICSI Membership Number: A16328 Encl: As above BIOCON LIMITED CIN: L24234KA1978PLC003417 Website: www.biocon.com Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE -560 100 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 (Rs. in Million, except per equity share data) Previous 3 months ended 3 months ended 3 months ended year ended 30.06.2026 31.03.2026 30.06.2025 SI. No. Particulars 31.03.2026 (Audited) (Unaudited) (Unaudited) (Audited) (Refer Note 17) 1 Income Revenue from operations 6,245 6,047 5,371 23,464 Other income 648 498 613 3,197 Total income 6,893 6,545 5,984 26,661 2 Expenses a) Cost of materials consumed 2,619 2,461 2,880 11,424 b) Purchases of stock-in-trade 65 211 452 c) Changes in inventories of finished goods, work-in-progress and 182 295 (543) (1,187) stock-in-trade d) Employee benefits expense 1,331 936 1,257 4,672 e) Finance costs 173 167 562 1,424 f) Depreciation and amortisation expense 384 362 333 1,373 g) Other expenses 1,440 1,562 1,366 5,848 6,194 5,783 6,066 24,006 Less: Recovery of cost from co-development partners (net) (6) (6) Total expenses 6,194 5,783 6,060 24,000 3 Profit/ (loss) before tax and exceptional items (1-2) 699 762 (76) 2,661 4 Exceptional items (net) [refer note 16] (188) (2,151) 5 Profit/ (loss) before tax (3 + 4) 699 574 (76) 510 6 Tax expense [refer note 16] Current tax charge/(credit) 167 (12) 11 120 Deferred tax charge/(credit) 10 76 (4) 18 7 Net Profit/ (loss) for the period/ year (5-6) 522 510 (83) 372 8 Other comprehensive income/ (loss) A (i) Items that will not be reclassified to profit or loss 98 69 (90) 48 (ii) Income tax relating to items that will not be reclassified to profit or loss (12) (12) 19 (3) B (i) Items that will be reclassified to profit or loss 40 (237) 7 (317) (ii) Income tax relating to items that will be reclassified to profit or loss (10) 59 (2) 80 Other comprehensive income/ (loss), net of taxes 116 (121) (66) (192) 9 Total comprehensive income/ (loss) for the period/ year (7+8) 638 389 (149) 180 10 Paid-up equity share capital (Face value of Rs. 5 each) 8,148 8,105 6,685 8,105 11 Reserves i.e. Other equity 2,62,693 12 Earnings per share (Face value of Rs. 5 each) (not annualised) (not annualised) (not annualised) (annualised) (a) Basic 0.32 0.32 (0.07) 0.27 (b) Diluted 0.32 0.32 (0.07) 0.27 See accompanying notes to the financial results BIOCON LIMITED CIN: L24234KA1978PLC003417 Website: www.biocon.com Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE -560 100 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 (Rs. in Million, except per equity share data) Previous 3 months ended 3 months ended 3 months ended year ended 30.06.2026 31.03.2026 30.06.2025 SI.No. Particulars 31.03.2026 (Audited) (Unaudited) (Unaudited) (Audited) (Refer Note 17) 1 Income Revenue from operations Sale of products 35,721 34,821 30,670 1,31,453 Sale of services 7,197 10,022 8,431 36,346 Other operating revenue 442 323 318 1,471 43,360 45,166 39,419 1,69,270 Other income 545 525 797 3,425 Total income 43,905 45,691 40,216 1,72,695 2 Expenses a) Cost of materials consumed 14,241 13,588 12,240 52,776 b) Purchases of stock-in-trade 3,819 2,226 8,371 13,626 c) Changes in inventories of finished goods, work-in-progress and (3,384) (1,821) (6,560) (9,495) stock-in-trade d) Employee benefits expense 9,161 9,121 8,331 35,080 e) Finance costs 2,132 2,315 2,767 9,903 f) Depreciation and amortisation expense 5,474 5,134 4,550 19,567 g) Other expenses 11,067 11,977 9,722 43,867 42,510 42,540 39,421 1,65,324 Less: Recovery of cost from co-development partners (net) (16) (128) (346) (1,137) Total expenses 42,494 42,412 39,075 1,64,187 3 Profit before share of profit of joint venture and associate, exceptional items and 1,411 3,279 1,141 8,508 tax (1-2) 4 Share of loss of joint venture and associate (net) - - - - 5 Profit before exceptional items and tax (3+4) 1,411 3,279 1,141 8,508 6 Exceptional items (net) [refer note 16] (135) (804) (172) (4,029) 7 Profit before tax (5 + 6) 1,276 2,475 969 4,479 8 Tax expense [refer note 16] Current tax charge/(credit) 1,158 2,506 667 4,436 Deferred tax charge/(credit) (1,250) (2,017) (590) (3,645) 9 Profit for the period/year (7 -8) 1,368 1,986 892 3,688 10 Other comprehensive income/ (loss) A (i) Items that will not be reclassified to profit or loss 5,425 2,091 (1,838) 4,267 (ii) Income tax relating to items that will not be reclassified to profit or loss (292) (111) 95 (223) B (i) Items that will be reclassified to profit or loss 3,001 7,594 (586) 15,487 (ii) Income tax relating to items that will be reclassified to profit or loss (246) 169 274 912 Other comprehensive income/ (loss), net of taxes 7,888 9,743 (2,055) 20,443 11 Total comprehensive income/ (loss) for the period/ year (9 + 10) 9,256 11,729 (1,163) 24,131 Profit/ (loss) attributable to: Shareholders of the Company 1,411 1,259 314 3,856 Non-controlling interest (43) 727 578 (168) Profit for the period/ year 1,368 1,986 892 3,688 Other comprehensive income/ (loss) attributable to: Shareholders of the Company 7,719 9,831 (2,049) 19,137 Non-controlling interest 169 (88) (6) 1,306 Other comprehensive income/ (loss) for the period/ year 7,888 9,743 (2,055) 20,443 Total comprehensive income/ (loss) attributable to: Shareholders ofthe Company 9,130 11,090 (1,735) 22,993 Non-controlling interest 126 639 572 1,138 Total comprehensive income/ (loss) for the period/ year 9,256 11,729 (1,163) 24,131 12 Paid-up equity share capital (Face value of Rs. 5 each) 8,148 8,105 6,685 8,105 13 Reserves i.e. Other equity 3,32,213 14 Earnings per share (Face value of Rs. 5 each) (not annualised) (not annualised) (not annualised) (annualised) (a) Basic 0.87 0.79 0.26 2.82 (b) Diluted 0.87 0.79 0.26 2.82 See accompanying notes to the financial results BIOCON LIMITED CIN: L24234KA1978PLC003417 Website: www.biocon.com Registered office: 20TH KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE -560 100 SEGMENT DETAILS OF UNAUDITED CONSOLIDATED RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 (Rs. in Million) Particulars 3 months ended 3 months ended 3 months ended Previous Year ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Audited) (Unaudited) (Unaudited) (Audited) (Refer Note 17) Segment revenue Biopharmaceuticals -Biosimilars 28,556 27,556 24,578 1,04,312 -Generics 7,597 7,760 6,303 28,754 Services 7,360 10,365 8,7 [Showing first 8,000 characters — download PDF for full document]